Why Is TG THERAPEUTICS INC (TGTX) Stock Up Today?

TG Therapeutics Inc stock rose 9.28% to $55.25 in early trading on August 21, driven by a combination of upgraded analyst price targets and improved sales guidance. The stock opened at $50.75 and reached a session high of $55.48 before settling near $54.55. The move follows a recent uptick in analyst activity and a revision of full-year revenue expectations.

What Happened

TG Therapeutics reported second-quarter sales of $240.335 million, exceeding the $229.721 million estimate. The company raised its full-year 2026 sales guidance from $925 million to $950 million, now slightly above the $942.37 million consensus estimate. Analysts from J.P. Morgan, B. Riley Securities, and HC Wainwright & Co. have all raised their price targets in recent days, with J.P. Morgan setting a new target of $72 and B. Riley Securities raising its target to $86. These developments contributed to the stock's sharp intraday rebound.

What The Data Shows

TGTX has a market capitalization of $7.3 billion and a P/E ratio of 18.3. The stock recently printed both a 52-week high and a 52-week low on the same day, illustrating the stock's volatility. Over the previous eight trading sessions, the stock had declined 7.9% from $53.48 to $49.23. The current session volume of 0.5 million shares is twice the 3-month average, indicating heightened interest. Meanwhile, former President Donald J. Trump has made multiple trades in the stock over the past 90 days, including two purchases and two sales, with the most recent filing on July 1.

What To Watch

The stock is approaching the upper end of its 52-week range of $26.76 to $59.30. Investors should monitor the breadth of analyst coverage and any further guidance updates from the company in the coming weeks.